cyrilzakka/clinical-trials huggingface dataset:
Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age.Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin . For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%.8 However, numerous reports of side effects, some lethal, have led to a decline in its use.

Since Dimson in 1977 reported on the effects of desmopressinl" several double blind, placebo controlled studies have shown the efficacy of the drug often with rapid effect but also often with immediate relapse after ending treatment.

While one of theory of nocturnal enuresis is deep sleep in children , this the main cornerstone in using Alarm as line of management .

On the other hand drugs used in rehabitation of sleep rhythm seems to be with great benefits in management as GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; antiinflammation; anti-tumor activities; anti-aging , and improve night sleep rhythm

Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age.Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin . For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%.8 However, numerous reports of side effects, some lethal, have led to a decline in its use.

Since Dimson in 1977 reported on the effects of desmopressinl" several double blind, placebo controlled studies have shown the efficacy of the drug often with rapid effect but also often with immediate relapse after ending treatment.

While one of theory of nocturnal enuresis is deep sleep in children , this the main cornerstone in using Alarm as line of management .

On the other hand drugs used in rehabitation of sleep rhythm seems to be with great benefits in management as GINKO BILOBA Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; antiinflammation; anti-tumor activities; anti-aging , and improve night sleep rhythm

Eligibility Criteria:
Inclusion Criteria:

* All patients with monosymptomatic nocturnal enuresis

Exclusion Criteria:

* patients with day and night enuresis
Attachment Image Data Set Validation in Adolescent

this study aims to validate a picture data set that particularly activates the attachment process and that could be used in attachment studies.

Pictures have been chosen to represent several emotions: distress, comfort, complicity and neutral.

Eligibility Criteria:
Inclusion Criteria:

* adolescent going to high school not hospitalized

Exclusion Criteria:

* mental retardation non comprehension of french visual deficit
Confocal Laser Endomicroscopy With Topical Cresyl Violet for Colorectal Polyps

Probe-based confocal laser endomicroscopy (pCLE) has been shown to a reliable diagnostic method enabling in vivo microscopic imaging during ongoing endoscopy. Usually fluorescein then serves as a contrast agent for pCLE, but it does not allow direct nuclear visualization, must be injected, leads to a transient skin discoloration, and may have allergic side effects. This study aimed to establish a single topical dye, cresyl violet (CV) for pCLE imaging, to describe pCLE interpretation criteria for the characterization of colorectal polyps with histopathological correlation, and to perform the validation of these criteria.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged from 18 to 75 years, with polyps found during surveillance or screening colonoscopies.

Exclusion Criteria:

* Contraindications to CV (such as allergy);
* Pregnancy or breastfeeding;
* Serous cardiopulmonary diseases, severe coagulopathy dysfunction, impaired kidney function;
* Inability to provide informed consent.
Study Evaluating Prevenar in High-Risk Children

The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.


Eligibility Criteria:
Inclusion Criteria:

* High-risk children ages 2 to 5 years old

Exclusion criteria:

* Prior administration of Prevenar
* Prior and/or concurrent administration of 23 vPs vaccine
Tinzaparin in the Treatment of the Acute Pulmonary Embolism

The purpose of this study is to evaluate the feasibility of the long-term treatment of pulmonary embolism with tinzaparin compared to oral anticoagulants.

The open-label prospective randomized clinical trial compares subcutaneous LMWH (tinzaparin) administered for 6 months versus initial treatment using subcutaneous LMWH followed by oral anticoagulants given for 6 months in patients with acute venous thrombosis.

To evaluate the direct and indirect cost of each treatment regimen in a rural population environment.

Eligibility Criteria:
Inclusion Criteria:

* Symptomatic pulmonary embolism patients confirmed by:

  * High probability ventilation/perfusion lung scan according to the PIOPED criteria
  * Spiral chest computed tomography, or
  * Pulmonary arteriography
* Aged 18 years or above, of either sex
* The patient must provide signed informed consent
* Patients will be agreed for receiving ambulatory anticoagulant treatment

Exclusion Criteria:

* Massive pulmonary embolism
* Allergy to heparin, other components of Tinzaparin or acenocoumarol
* Previous thrombocytopenia induced by heparin
* Thrombocytopenia \< 100000/mm3
* History/signs/symptoms of congenital bleeding disorder
* Life expectancy less than 90 days
* Unfractioned heparin anticoagulation for more than 36 hours prior enrollment
* Inability to participate in the home tinzaparin program
* Clinical overt gastrointestinal blood loss due to peptic ulcer, intestinal tumours, oesophagitis or diverticulosis
* Hemoglobin lower than 7 g/dL or Creatinin \> 3mg/dL
* Cerebral-vascular accident
* Cerebral, medullary and ophthalmological surgery
Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging

Response Prediction after Gamma Knife Surgery (GKS) in Patients with Vestibular Schwannoma using Dynamic Contrast-Enhanced (DCE) MR Imaging

The purpose of this study was to evaluate the response of Gamma Knife Surgery to Ktrans, Ve, and Vp, which are indicators of permeability map obtained from dynamic contrast enhanced (DCE) MRI in patients with vestibular schwannoma .

Eligibility Criteria:
Inclusion Criteria:

* Patients with vestibular schwannoma, who underwent gamma knife surgery and pre-op dynamic contrast enhanced (DCE) MRI
* Patients with vestibular schwannoma, who received consent

Exclusion Criteria:

* In addition to the vestibular schwannoma, if the brain has other underlying or systemic disease
* During the observation period, other treatments were performed other than gamma knife surgery
* If patients have a contraindication to MRI (eg, pacemaker, cochlear implants, hemodynamically unstable)
* Concomitant use of gadolinium MRI contrast agents (eg, renal insufficiency \[glomerular filtration rate \<30 ML / min\]), or if there was a side effect when using a contrast medium.
* Adults with impaired ability to cope
* If the images and medical records required for this study are not available or are not appropriate
Effects of Acupuncture-assisted Rehabilitation Protocol for Achilles Tendon Rupture

This prospective study is to compare the rehabilitation effect between the patients with achilles tendon rupture using traditional rehabilitation protocol and acupuncture-assisted rehabilitation protocol. The main question it aims to answer is whether acupuncture is an effective rehabilitation treatment. The patients are divided into the traditional rehabilitation group and acupuncture assisted rehabilitation group. The time of return to light sports activity and other indicators of the two groups will be compared.

This prospective randomized controlled clinical study is designed to compare the treatment outcomes of different rehabilitation protocols by dividing the patients into two groups-based on the traditional rehabilitation protocol and acupuncture-assisted rehabilitation protocol. See the text for detailed inclusion and exclusion criteria. Patients that meet all the inclusion criteria but do not meet any exclusion criteria, and who have signed the informed consent will be recruited, and each patient will be assigned a unique patient identification number, which will be used throughout the study identify the patient. All patients be treated surgically with the same suture technique. For acupuncture-assisted rehabilitation group, patients will receive additional acupuncture treatment. Investigators will collect indicators from multiple dimensions such as ankle function and pain level to compare the efficacy of the two groups.

The achilles tendon , despite being the largest and strongest tendon, is often prone to ruptures. The latest evidence48 has demonstrated that at centers using functional rehabilitation, nonoperative treatment results in similar rerupture rates but significantly lower complica- tion rates than surgical treatment. So we expect this trial to point out better rehabilitation.

In traditional Chinese acupuncture, nearly 400 acupoints on the body surface are interrelated to various functions. Acupuncture has also been widely studied for the treatment of motor system diseases. However, trials on rehabilitation of Achilles tendon rupture are still lacking.

Eligibility Criteria:
Inclusion Criteria:

* acute closed single-legged complete Achilles tendon rupture
* age of 18 to 60 years.

Exclusion Criteria:

* patients with prior Achilles tendon rupture or other situations that affected their lower limb functions or tendon healing (e.g., autoimmune disease, diabetes mellitus, systemic corticosteroid treatment).
* an inability to complete our suture technique (e.g., the distance from the rupture site to the Achilles tendon insertion was less than 3.5 cm) .
* those without rehabilitation or follow-up outcomes.
Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery

aimed at investigating the efficacy, safety, and clinical outcome of Medium-Calorie or standard-calorie total parenteral nutrition (TPN) for patients with gastrointestinal cancer undergoing surgery

biochemistry data Various inflammation-related cytokines clinical outcome hospital stay

Eligibility Criteria:
Inclusion Criteria:

* Patients considered for major surgery for colorectal cancer Expected requirement for post operative PN or TPN of at least for 7 days Age \>18 Hemodynamically stable Written Informed Consent

Exclusion Criteria:

* Hemodynamic failure of any organ Renal insufficiency Patients with severe liver dysfunction Albumin \< 3g/dL DM with poor blood sugar control
Avenir® Cemented Hip Stem - PMCF

The objective of this post-market clinical follow-up study is to confirm the safety and performance of the Avenir® Cemented Hip stem when used in primary total hip arthroplasty.

This is a multicenter, prospective, non-controlled post-market clinical follow-up study to fulfill the post market surveillance obligations according to Medical Device Directive and MEDDEV 2.12-2.

The objectives of this study are to confirm the safety and performance of the Avenir Cemented Hip Stem when used in primary total hip arthroplasty at 6 weeks to 6 months, 1, 2, 3, 5, 7 and 10 years post-operatively.

The Avenir Cemented Hip Stem is a straight double-tapered stem offering 9 standard and 9 lateralized versions, the same as the uncemented version, the Avenir-Mueller Stem.

Safety will be evaluated by monitoring the frequency and incidence of adverse events and through radiographic review.

Performance will be based on the implant survival, overall pain and functional performances, subject quality-of-life and radiographic parameters of study subjects who received the Avenir® Cemented Hip stem.

Implant survival will be based on removal or intended removal of the device.

A total of 130 patients will be enrolled into the study at up to 4 sites.

Eligibility Criteria:
Inclusion Criteria:

* Patient is 18 years of age minimum.
* Patient is suffering from severe hip pain and disability requiring primary unilateral or bilateral total hip arthroplasty based on physical exam and medical history.
* Patient is willing and able to cooperate in the required post-operative therapy.
* Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

Exclusion Criteria:

* Patient is unwilling or unable to give consent, or to comply with the follow-up program.
* Acute, chronic, local, or systemic infections.
* Severe muscular, neural, or vascular diseases that endanger the limbs involved.
* Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible.
* Total or partial absence of the muscular or ligamentous apparatus.
* Any concomitant diseases that can jeopardize the functioning and the success of the implant.
* Allergy to the implanted material, especially to metal (e.g., stainless steel).
* Local bone tumors and/or cysts.
* Pregnancy
* Skeletal immaturity
* Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, a known drug abuser or alcoholic or anyone who cannot understand what is required of them.
* Patients with plans to relocate during the study follow-up period.
* For patients biologically younger than 60 years with joint disease, a different reconstruction operation (e.g., osteotomy) or arthrodesis may be indicated.
Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation

Visceral hypersensitivity as evidence of central sensory sensitization is evident in many patients with functional disorders such as functional dyspepsia (FD) and irritable bowel syndrome (IBS). We recently demonstrated both somatic hypersensitivity and abnormal endogenous pain modulation in IBS, both of which indicate central sensitization as a crucial mechanism in IBS. Endogenous pain mechanisms regulate, fine-tune and integrate sensory and homeostatic, including neuroendocrine, immune, motor and autonomic nervous system processes. Hitherto, no studies have investigated the role endogenous pain modulation in FD. Abnormal modulation could explain several of the symptom complexes associated with FD and provide a rationale for exploration of new treatments.

The current study was designed to

1. investigate the gastric sensitivity in FD patients and healthy controls during gastric capsaicin stimulation
2. assess the endogenous pain inhibitory modulation system in FD patients and healthy controls during heterotopic stimulation


Eligibility Criteria:
Inclusion Criteria:

FD patients:

* Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks.
* FD discomfort or pain should be the most prominent symptom.
* Patients must have been off all FD and analgesic medication and any drugs potentially influencing sensory function for at least two weeks before study start and be able to remain off such medication for the duration of the study period.

Healthy controls:

* Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.

Exclusion Criteria:

Exclusion criteria for both FD patients and healthy controls:

* Organic gastrointestinal or other significant systemic disease, including cardiovascular, dermatological, psychiatric, neurological and endocrine diseases. Patients with peptic ulcer scars are also excluded.
* Chronic or acute pain, except related to other functional syndromes (irritable bowel syndrome, chronic pelvic pain, fibromyalgia, migraine).
* H. pylori positive.
* Abdominal surgery, including gastric resection or cholecystectomy (except appendectomy)
* History of brain disease or brain surgery.
* Ongoing treatment with any drugs or need for drugs (or complementary medication) within last 14 days.
* Treatment with any investigational drug during the preceding 30 days.
* Ingestion of spicy, chilli pepper containing meal, or use of capsaicin skin cream in last 48 hours before start of study or any study day.
* Pregnancy or lactation.
* No written informed consent obtained from subject.
Confirming Feeding Tube Position Using CORTRAK

This study will compare the accuracy of the CORTRAK enteral access system (CEAS) to x-ray for the determination of feeding tube position within the abdomen.

In the inpatient pediatric care area (PICU, PCCU, PIMU, ACU), when an x-ray is performed for any reason and a patient has a CORTRAK feeding tube, a provider from the research team will re-insert the small, individualized, flexible stylet back into the patient's feeding tube and document the position of the tube on the CORTRAK display monitor. The x-ray will be obtained by current standard of care and the tube location on x-ray will be compared to the tube location on the CORTRAK monitor. The x-ray will only be obtained as part of the routine care decided by the medical team, the patient will not receive any additional x-rays for this study.

Eligibility Criteria:
Inclusion Criteria:

* CORTRAK feeding tube placed as part of clinical care
* Getting xray for any reason
* CORTRAK Stylet available in the room
* Pediatric patients (Aged 17 or younger)

Exclusion Criteria:

-CORTRAK Stylet has been misplaced
To Study the Effects of Baby Drink on Vision Care

Baby Drink is a formula based on lutein, mixed with blueberry fermented liquid, vitamins and minerals. Lutein is an effective antioxidant to prevent retinal damage caused by blue light, but it cannot be produced in the human body and depends on dietary intake. Blueberry fermented liquid is rich in polyphenolic compounds with excellent antioxidant capacity and the potential to reduce oxidative damage to eye cells caused by ultraviolet rays. With the prevalence of 3C products, myopia patients are increasing year by year in various regions, and suffer from eye diseases or vision loss with different degrees of complications. In this study, the subjects were provided with Baby Drink and tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. The aim of this study is to investigate the protection of Baby Drink on visual acuity and visual fatigue.

1. Visual acuity measurement: Snellen's Chart was used to measure visual acuity.
2. Refractive examination: Measure binocular refraction with Open Field computer refractor (Shin-Nippon Nvision K5001 Wide View).
3. Measuring the axial length of the eye: Use the multifunctional optical eyeball length measuring instrument (Lenstar) to measure the distance from the instrument to the optical paths such as the cornea, lens, and retina, and then convert to the axial length of the eye.
4. Corneal radian measurement: Use a keratometer (Bausch \& Lomb Keratometer) to measure the corneal radian and curvature, and estimate the degree of corneal astigmatism.
5. Visual fatigue questionnaire survey: A visual fatigue scale questionnaire was designed using Ocular Surface Disease Index (OSDI) and Computer Vision Syndrome (CVS).

Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 20 or over
2. Willing to participate in this study and sign the subject's consent form
3. Myopia less than 700 degrees

Exclusion Criteria:

1. Have consumed related eye care products in past 3 months
2. Those who have eye infection in the past 3 months
3. People who have been diagnosed with any eye diseases in past 3 months
4. Those who are allergic to cicadae
Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults

This study will evaluate the safety and tolerability of the probiotic Lactobacillus reuteri (LR) in healthy adult patients. Patients will be randomized to receive either LR or placebo orally each day for a total of 60 doses. The effects on fecal bacteria, circulating white blood cell receptors and inflammatory cytokine profiles will be measured.

Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract micro flora and prevention and treatment of mild diarrhea associated with GI-tract infections. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938. The patients will receive 5 drops (10\^8 live organisms) by mouth daily for 60 days. Daily administration will include 5 drops (5x10\^8) of L. reuteri or placebo daily for two months. During this time,circulating peripheral blood mononuclear cell (PBMC) toll-like receptor-2 and -4 levels will be measured, along with PBMC cytokine production levels in vitro. Fecal DGGE analysis(with sequencing of bacterial rDNA) will be completed identifying changes in fecal microbiota. Inflammation in the gut will also be assessed by fecal calprotectin assay (ELISA). The time on study treatment is 2 months, with 4 months observation, for a total of 6 months. There will be 7 required visits, during which, we will assess safety and immune system effects.

Eligibility Criteria:
Inclusion Criteria:

* Healthy Adults (18 - 60 years old)
* No other recognized illness

Exclusion Criteria:

* Pregnancy or breastfeeding
* Patient taking immunosuppressive medications, including oral corticosteroids
* Positive result of HIV, Hepatitis B, and/or Hepatitis C test
* Abnormal lab test results
* Gastrointestinal related diseases and surgeries
* Patients with an allergy to antibiotics
* Presence of fever or a pre-existing adverse event monitored in the study
* No more than two study participants in one household
* Use of probiotics in the last 90 days
* Diarrheal illness within the past 30 days
* Recent or current use of oral antibiotics /anti-fungals(in the past 2 weeks)
* Current use of oral laxatives
* Chronic alcohol use or more than 1 drink per day
* Subjects with implanted prosthetic devices including prosthetic heart valves
* Known sensitivity to sunflower oil or products containing linolenic/oleic acids
* Will require that subject not take any other probiotic-containing products, including yogurt supplemented with probiotics during the 6-month period